R Heyne

University of Nebraska–Lincoln

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Thomas Berg

University Hospital Leipzig

Stefan Mauss

Center for HIV and Hepatogastroenterology

C John

Orthopädische Praxis

U. Alshüth

Roche Pharma AG (Germany)

Peter Buggisch

Institute for Interdisciplinary Medicine

G Teuber

Orthopädische Praxis

D Hüppe

Praxis für Humangenetik

D. Hueppe

Center for HIV and Hepatogastroenterology

Markus Cornberg

Medizinische Hochschule Hannover

Gero Moog

Marienkrankenhaus Kassel

Cooperative Institutions

Goethe University Frankfurt

235

University Hospital Frankfurt

210

German Center for Infection Research

206

St. Josefs Hospital

Charité - Universitätsmedizin Berlin

European Foundation for the Study of Chronic Liver Failure

University Hospital Leipzig

Medizinische Hochschule Hannover

Inserm

Universität Hamburg

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

PNPLA3 and HSD17B13 gene variants exert opposite effects on fatty liver phenotypes: results from the FLAG cohort

Zeitschrift für Gastroenterologie (2020)

Marcin Krawczyk Jörn M. Schattenberg Lisa Schubert Nektarios Dikopoulos Jeannette Schwenzer

Non-alcoholic fatty liver disease (NAFLD) is a prevalent condition common in overweight and obese individuals. The PNPLA3 p.I148 M variant represents a major genetic determinant of NAFLD progression. Recently the loss-of-function HSD17B13 polymorphism rs72613567 was reported to be hepatoprotective in patients with chronic liver diseases (Abdul-Husn et al. NEJM 2018). Here we investigate the effects of the PNPLA3 and HSD17B13 variant on NAFLD phenotypes in a "real life" cohort of German NAFLD patients.

Flag (linear algebra)

Chronic liver disease

10.1055/s-0039-3402166

Cite

Citations (0)

Response to discontinuation of nucleos(t)ide analogue treatment in HBeAg-negative chronic hepatitis B: results from the Stop-NUC trial

Zeitschrift für Gastroenterologie (2020)

Florian van Bömmel Kerstin Stein R Heyne Holger Jon Møller J. Petersen

Background and aims Discontinuation of long-term suppression of HBV replication with nucleos(t)ide analogues (NUCs) can result in durable immune control of hepatitis B virus (HBV) replication in HBeAg negative patients. We have assessed the effect of NUC discontinuation in HBeAg negative patients in a prospective, multicenter, randomized trial (the Stop-NUC study).

Discontinuation

HBeAg

Hepatitis B

10.1055/s-0040-1716038

Cite

Citations (0)

Re: Zinc levels in neonatal life influence long-term neurodevelopment

Journal of Perinatology (2021)

Luc P. Brion R Heyne Cheryl S. Lair

Neonatology

10.1038/s41372-021-01013-w

Cite

Citations (0)

1092 EFFECTS OF PRE-TREATMENT WITH BEZAFIBRATE FOLLOWED BY STANDARD OF CARE IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 INFECTION AND ELEVATED GGT LEVELS

Journal of Hepatology (2012)

Albrecht Böhlig V Weich Michael Biermer Rajesh Somasundaram Holger Hinrichsen

Bezafibrate

10.1016/s0168-8278(12)61104-0

Cite

Citations (1)

Pathological Glucose Levels and Presence of Hypertension Identifies HCV Patients With Minor Treatment Responses

Gastroenterology (2011)

Elmar Jaeckel E Zehnter Thomas A. Lutz Karl-Heinz Hey Christine John

10.1016/s0016-5085(11)63867-5

Cite

Citations (0)

Clinical management of prescribed co-medication in patients treated with OBV/PTV/r ± DSV ± RBV – Data from the German observational study LIFE-C

Zeitschrift für Gastroenterologie (2018)

Peter Buggisch R. Link Uwe Naumann G Teuber R Heyne

Clinical trials and real-life data often focus on the safety and efficacy/effectiveness of ombitasvir/paritaprevir/r ± dasabuvir ± ribavirin (RBV). We conducted a large non-interventional observational study (LIFE-C) to assess effectiveness and safety, but also to learn more about key patient characteristics (i.e., comorbidities and co-medication) and the clinical management of prescribed co-medication in patients treated with ombitasvir/paritaprevir/r ± dasabuvir ± RBV in Germany.

Ombitasvir

Dasabuvir

Paritaprevir

10.1055/s-0037-1612888

Cite

Citations (0)

Angstfaktor „Therapie der Hepatitis C“: Gründe, warum Patienten eine Behandlung mit Peginterferon und Ribavirin ablehnen

Zeitschrift für Gastroenterologie (2006)

D Hüppe Stefan Mauss C John R Heyne B Möller

Einleitung: Zur Messung der Qualität der Behandlung von Patienten mit Hepatitis C führt der Bundesverband niedergelassener Gastroenterologen (bng) in Kooperation mit Hoffmann-La Roche eine deutschlandweite online-AWB bestehend aus Screening- und Therapiedokumentation durch. Von März 2003 bis September 2005 wurden 9414 Screeninguntersuchungen dokumentiert, davon wurden 5413 Patienten unter Angabe verschiedener Gründe nicht behandelt. Patientenwunsch war mit 29,1% (n=2739) der Hauptgrund, wobei davon 42,6% Angst vor der Therapie anführten.

10.1055/s-2006-950872

Cite

Citations (0)

Genetic variants of interleukin 1 beta are associated with viral hepatitis-related HCC in Caucasian patients

Zeitschrift für Gastroenterologie (2021)

Janett Fischer Sarah S. Long Eleni Koukoulioti Tobias Müller B Fueloep

Background The proinflammatory cytokine interleukin 1 beta (IL-1b) mediates several immune responses and promotes the development of liver cirrhosis and hepatocellular carcinoma (HCC). Alterations in the IL-1b gene can affect cytokine expression and signaling and can augment the progression of liver disease towards more severe stages. We aimed to investigate the association of polymorphisms within the promotor region of the IL-1b gene with liver disease progression in Caucasian patients related to chronic infection with hepatitis B virus (HBV) and hepatitis C virus (HCV).

Proinflammatory cytokine

Liver disease

Hepatitis C

10.1055/s-0040-1722060

Cite

Citations (0)

Klinische Marker des metabolischen Syndroms sind häufiger mit HCV Genotyp 1 Infektion assoziiert und sind starke negative Prädiktoren für eine EVR

Zeitschrift für Gastroenterologie (2010)

Elmar Jaeckel E Zehnter C John T Lutz Wolfgang Schmid

Einleitung: Insulinresistenz (IR) wurde bei Patienten mit chronischer Hepatitis C (HCV) nachgewiesen. Die Assoziation mit speziellen Genotypen ist noch umstritten. Es wurde beobachtet, dass IR & Präsenz des metabolischen Syndroms negativen Einfluss auf die antivirale Therapie haben können.

10.1055/s-0030-1263891

Cite

Citations (0)

Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease - Data from the German Hepatitis C-Registry (DHC-R)

Zeitschrift für Gastroenterologie (2020)

K.M. Stein Albrecht Böhlig Albrecht Stoehr Hartwig Klinker G Teuber

Background and aims Grazoprevir/elbasvir (GZR/EBR) and glecaprevir/pibrentasvir (G/P) are two treatment options for patients with chronic hepatitis C and a baseline glomerular filtration rate (GFR) < 30 ml/min. Real world data in this special patient population is sparse so far. Thus, we analyzed safety and effectiveness data within the German Hepatitis C-Registry (DHC-R).

10.1055/s-0040-1716035

Cite

Citations (2)